THE FDA has confirmed that it is reviewing documents from Glaxo to see whether damaging information about heart attacks caused by its Diabetes drug might have been hidden from the agency. FDA reviewer Robert Misbin, an expert on Diabetes drugs spotted an analysis back in 2006 on Avandia done by an FDA statistician which showed a 31% increase in heart attack risk later found to be 43%. So far, the drug has not been pulled from the market but has increased warnings. However, if Glaxo is found to have secreted important data, that situation might change.